Baxter International (NYSE:BAX) updated its FY 2020
Pre-Market earnings guidance on Thursday. The company provided EPS guidance of 3.00-3.10 for the period. The company issued revenue guidance of $11.248-11.476 billion, compared to the consensus revenue estimate of $11.72 billion.Baxter International also updated its FY20 guidance to $3.00-3.10 EPS.
A number of research analysts have weighed in on the company. Morgan Stanley decreased their price objective on Baxter International from $95.00 to $90.00 and set an equal weight rating on the stock in a report on Friday. TheStreet upgraded Baxter International from a c+ rating to a b+ rating in a report on Thursday, April 30th. Wells Fargo & Co raised their price objective on Baxter International from $92.00 to $104.00 and gave the company an overweight rating in a report on Monday, April 20th. JPMorgan Chase & Co. raised their price objective on Baxter International from $94.00 to $96.00 and gave the company an overweight rating in a report on Tuesday, April 28th. Finally, KeyCorp lifted their price target on Baxter International from $92.00 to $98.00 and gave the stock an overweight rating in a report on Friday, May 1st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $96.72.
Shares of NYSE BAX opened at $86.38 on Friday. The company has a current ratio of 2.74, a quick ratio of 2.19 and a debt-to-equity ratio of 0.84. Baxter International has a twelve month low of $69.10 and a twelve month high of $95.19. The stock has a 50 day moving average of $86.00 and a two-hundred day moving average of $86.95. The stock has a market cap of $43.81 billion, a P/E ratio of 26.74, a P/E/G ratio of 2.76 and a beta of 0.84.
Baxter International (NYSE:BAX) last issued its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $0.64 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.71 by ($0.07). Baxter International had a net margin of 8.10% and a return on equity of 21.02%. The firm had revenue of $2.72 billion during the quarter, compared to analysts’ expectations of $2.86 billion. During the same quarter in the prior year, the firm posted $0.89 EPS. Baxter International’s quarterly revenue was down 4.3% compared to the same quarter last year. As a group, research analysts predict that Baxter International will post 3.07 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Shareholders of record on Monday, August 31st will be paid a $0.245 dividend. This represents a $0.98 dividend on an annualized basis and a yield of 1.13%. The ex-dividend date of this dividend is Friday, August 28th. Baxter International’s dividend payout ratio is currently 29.61%.
In other news, Director John D. Forsyth sold 1,500 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $82.95, for a total value of $124,425.00. Following the transaction, the director now owns 35,398 shares of the company’s stock, valued at $2,936,264.10. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Giuseppe Accogli sold 72,341 shares of the business’s stock in a transaction that occurred on Friday, June 19th. The shares were sold at an average price of $85.00, for a total value of $6,148,985.00. Following the completion of the transaction, the senior vice president now directly owns 76,473 shares in the company, valued at approximately $6,500,205. The disclosure for this sale can be found here. In the last quarter, insiders sold 77,583 shares of company stock valued at $6,613,932. 0.13% of the stock is owned by company insiders.
About Baxter International
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Further Reading: What sectors are represented in the Hang Seng index?
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.